Potent Inhibition of Acid Ceramidase by Novel B-13 Analogues by Proksch, Denny et al.
Hindawi Publishing Corporation
Journal of Lipids
Volume 2011, Article ID 971618, 8 pages
doi:10.1155/2011/971618
Research Article
Potent InhibitionofAcid CeramidasebyNovel B-13Analogues
Denny Proksch, JanJasperKlein,andChristophArenz
Institut f¨ ur Chemie, Humboldt Universit¨ at zu Berlin, Brook-Taylor-Str 2, 12489 Berlin, Germany
Correspondence should be addressed to Christoph Arenz, christoph.arenz@chemie.hu-berlin.de
Received 28 July 2010; Revised 1 October 2010; Accepted 26 October 2010
Academic Editor: Angel Catala
Copyright © 2011 Denny Proksch et al.Thisisanopenaccessarticledistributed undertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The lipid-signalling molecule ceramide is known to induce apoptosis in a variety of cell types. Inhibition of the lysosomal acid
ceramidase can increase cellular ceramide levels and thus induce apoptosis. Indeed, inhibitors of acid ceramidase have been
reported to induce cell death and to display potentiating eﬀects to classical radio- or chemo therapy in a number of in vitro and in
vivo cancer models. The most potent in vitro inhibitor of acid ceramidase, B-13, recently revealed to be virtually inactive towards
lysosomalacid ceramidase in living cells. In contrast, a number of weakly basic B-13 analogues have been shown to accumulate in
the acidic compartments of living cells and to eﬃciently inhibit lysosomalacid ceramidase. However, introduction of weakly basic
groups at the ω-position of the fatty acid moiety of B-13 led to a signiﬁcant reduction of potency towards acid ceramidase from
cellular extracts. Herein, we report a novel B-13-derived scaﬀoldfor more eﬀective inhibitors ofacid ceramidase.Furthermore, we
provide hints for an introduction of basic functional groups at an alternative site of the B-13 scaﬀold that do not interfere with
acid ceramidase inhibition in vitro.
1.Introduction
Besides their function as constituentsof cellular membranes,
sphingolipids play an important role as signalling molecules.
They have essential functions for cell growth, cell diﬀerentia-
tion, and cell death (apoptosis), thus being indispensable for
cell homeostasis and normal cell development.Especially the
equilibriumbetweenceramideandsphingosine-1-phosphate
(S1P) seems to be decisive for a ﬁnal cellular response [1–
4].Thecellular“sphingolipidrheostat” isprimarilyregulated
by three classes of enzymes: the ceramide generating sph-
ingomyelinases, the ceramide degrading ceramidases, and
ﬁnally the sphingosine kinases. Further enzymes controlling
ceramide levels are the sphingomyelin synthases [5–7]a n d
the glucocerebroside synthase [8].
Ceramide often accumulates after stimulation of cells
with stress factors like inﬂammatory cytokines, UV radi-
a t i o n ,X - r a y s ,h e a ts h o c k ,a n do x i d a t i v es t r e s s .A sac o n -
sequence to such primary triggers, neutral or acid sphin-
gomyelinases (nSMase or aSMase) are activated, in which
both cleave sphingomyelin to form ceramide [9, 10]. The
exact mechanism, by which the respective SMases are
activated, is still not completely understood. Small molecule
inhibitors that speciﬁcally act on the various sphingolipid-
degrading enzymes can help in clarifying the underlying
mechanisms. Recently, we developed a number of potent
and speciﬁc inhibitors of the acid sphingomyelinase, which
inhibited dexamethasone-induced apoptosis in HEK-293
cells, respectively [11–13]. The action of SMases, however,
controls only the inﬂux of ceramide and thus only partially
contributes to understanding cellular ceramide concentra-
tion. The contribution coming from the degradation of
ceramide by ceramidases (CDases) is similarly important.
Several diﬀerent CDases exist, which can be charac-
terized by their diﬀerent pH-optima (e.g., neutral [14]
and alkaline [15]) and subcellular localization. The acid
ceramidase (aCDase) is doubtlessly indispensable for the
cellular ceramide degradation, and a deﬁciency in acid
ceramidase leads to Morbus Farber, a recessively inherited
lysosomal storagedisease characterized by massive lysosomal
ceramide accumulation. Patients have a strongly limited
life expectancy and—depending on the residual enzyme
activity—die within a few years. The phenotype of the
classical form (type 1) includes progressive articular defor-
mations, subcutaneous lumps, inﬂammatory granulomas,
and progressive neurological dysfunction [16]. The aCDases2 Journal of Lipids
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Figure 1: Current lead structures for the development of CDase inhibitors.
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Figure 2: Someof the basic analogues of D-MAPPand B-13 developed by Gatt et al. (LCL 204, LCL 385) and by Bielawskaet al. (LCL 464).
from human [17]a n dm o u s e[ 18] have been cloned. The
enzyme is localized to the lysosomes [19]o ri ss e c r e t e d
extracellularly [20].
The aCDase was shown to be upregulated in prostate
cancer [21] and melanomas [22], which lead to the hypoth-
esis that the aCDase could be a tumour marker [22,
23]. Moreover, aCDase in tumour cells obviously confers
resistance to chemo- and radiotherapy [24] thus making the
inhibitionofthisenzymeapotentialtargetforcancertherapy
[25].
At present, there are three diﬀerent lead structures
for aCDase inhibitors (Figure 1) .T h ea C D a s ei ss e l e c t i v e l y
inhibited by B-13 with an IC50 of about 10μMa n dl e s s
potently by N-oleoylethanolamine (NOE, Ki ∼ 500μM).
D-MAPP, which is structurally related to B-13, has been
reported to selectively inhibit alkaline ceramidase [15]
activity derived from HL-60 cell extracts with an IC50 of
about 1–5 μM[ 26]. In another report, however, D-MAPP
is a moderate but selective inhibitor of aCDase in human
melanoma and HaCaT cells [27].
The mechanism of ceramidase inhibition for all these
substances is currently unknown. The three lead structures,
B-13, NOE, and D-MAPP, can be obtained by a single syn-
thetic step from commercially available chemicals [28], thus
making them attractive starting points for combinatorial
chemistry and SAR studies.
Because of their potential as anticancer drugs, several
novel ceramidase inhibitors have been developed recently.
From a collection of NOE analogues, two compounds not
only inhibited aCDase in cell culture (IC50 ∼ 15μM), but at
t h es a m et i m ee x h i b i t e dc y t o t o x i c i t yt oA 5 4 9c e l l s( I C 50 ∼
40μM) [29, 30]. The screening of these potential CDase
inhibitors has been facilitated by a ﬂuorescent ceramidase
probe allowing for high-throughput screening of CDase
inhibitors in vitro and in cell culture [31]. In an eﬀort to
improve the activity of B-13 and D-MAPP in vitro and in
cell culture, Bielawska and colleagues recently conducted
several very detailed and interesting studies. In an attempt to
develop aCDase inhibitors that accumulate in lysosomes, B-
13 and D-MAPP analogues carrying basic functional groups
have been evaluated (Figure 2)[ 32–34]. Several of these
compounds were synthesized before in the group of Shimon
Gatt [35, 36].
Similar to the tricyclic antidepressants imipramine
and desipramine [37], these molecules are in equilibrium
between the protonated cationic form and the unprotonated
neutral form. Only the latter can permeate lysosomal mem-
branes and enter the lysosomes. In the acidic environment
of the lysosomes, these substances immediately get fully
protonated.Very rapidly,asaconsequenceofthesteady-state
equilibrium,nearlythewholeportionofthesubstancecanbe
found in the lysosomes, thereby increasing its eﬀectivein situ
concentration.
Indeed, the substances LCL 204, LCL 385, and LCL 464
accumulated in the acidic compartments of the cells, while
the neutral analogues showed no spatial preference.
Interestingly, the lysosomotropic aCDase inhibitor LCL
204 was shown to induce apoptosis in prostate cancer cellsJournal of Lipids 3
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Figure 3: Retrosynthetic analysis of the B-13/D-MAPP scaﬀold.
[38] and to enhance the cytotoxicity of the viral protein
apoptin in prostate cancer [39]. This compound is also
active in head and neck squamous cell cancers (HNSCCs)
in vitro and in vivo in a xenograft model sensitizing cells to
Fas ligand-induced apoptosis [40]. In addition, the closely
related analogue LCL-385, sensitized PPC-1 prostate cancer
cellstoradiation andsigniﬁcantlydecreasedtumorxenograft
growth [41].
A more detailed biochemical investigation, however,
revealed that LCL 204 (and probably also LCL 385) induce
unwanted lysosomal permeabilization and degradation of
aCDase [34]. A similar mode of action is known for the
tricyclic antidepressants. These positively charged agents
induce proteolytic degradation of acid sphingomyelinase
and probably of acid ceramidase by blocking the negatively
charged lipid bis(monoacylglycero)phosphate (BMP) [42],
which is speciﬁc to the membranes of intralysosomal
vesicles and has proven indispensable for the action of
many sphingolipid hydrolases. Obviously, BMP promotes
the binding of sphingolipid hydrolases and sphingolipid
activator proteins (SAPs) to the intralysosomal membranes
thereby protecting these proteins from proteolytic degrada-
tion. Recent investigation showed that BMP is essential for
the binding of lysosomal Hsp70 which promotes lysosomal
integrity [43]. Thus, agents comprising basic groups that
may be protonated in the lysosomes have the potential to
act by perturbing lysosomal integrity. In fact, similar to the
tricyclic antidepressants, LCL 204 hardly inhibits aCDase
from cell extracts (5% inhibition at 50μM). In contrast, B-
13 (95%) is much more potent in cell extracts but revealed
being virtually inactive against aCDase activity in intact
MCF7 cells, probably due to its inability to accumulate in
cellular lysosomes. The reason for the marked increase in
cellular ceramide caused by B-13 is currently unknown.
It has to be noted that in an earlier study, LCL 204
(AD2646) showed an IC50 of 42μM[ 44], underscoring
the importance of using puriﬁed enzymes for SAR stud-
ies.
A second generation basic B-13 analogue, LCL 464,
was shown to inhibit CDase activity in cell extracts (50%
at 50μM). Compared to LCL 204 this compound is not
only more potent in cellular extracts, but also shows
superior inhibition of a CDase in living cells, without
reducing the amount of aCDase at the protein level [34].
These results show that the cellular inhibition of acid
ceramidase depends on both, the in vitro activity and
the ability to accumulate in cellular lysosomes. The lat-
ter feature is dependent on the presence of basic moi-
eties.
2.Results
The molecular basis of the ceramidase inhibition by
D-MAPP and B-13 is still unknown. Accordingly, the
possibilities for a rationallydriven synthesis of improved
inhibitors are limited. Small libraries of compounds with
systematically altered functional groups or stereochemistry
can provide information about structural requirements for
binding to ceramidases. Preceding the investigation of the
structure-activity relationship (SAR) for B13-inhibiting acid
ceramidase, we did a retrosynthetic analysis of the B-13/D-
MAPP scaﬀold. It is known that the base of D-MAPP,
norephedrine, can easily be obtained by nitroaldol reac-
tion (“Henry reaction”) of nitroethane with benzaldehyde
and subsequent reduction (see retrosynthetic analysis in
Figure 3).
The retrosynthetic analysis revealed three variable moi-
eties, an aromatic part (Ar), a nitrogen-bound substituent
R2,a n dan i t r o c o m p o n e n t( O 2N–CH2–R1). The simplest
organic nitro component is nitromethane (R1 = H), leading
to bases of type 3 (Figure 4). In our initial activity screening,
the B-13 analogue DP24a displayed a remarkable inhibitory
activity towards the recombinant human aCDase (Figure 5).
In a more detailed study, the IC50 value was determined at
1.287μM( Figure 6).
The B-13 lead structure contains an aromatic nitro
group which decreases electron density of the aromatic
ring (−Me ﬀect). We wanted to test whether electron
donors like methoxy groups (+M eﬀect) would inﬂuence
the inhibitory properties of our compounds. Reaction of
3-methoxy benzaldehyde 1b with nitromethane yielded the
nitrocompound 2b. Catalytic hydrogenation of the latter
aﬀorded 3b, which was treated with myristoyl chloride to
give the ﬁnal B-13 analogue DP24b.A tac o n c e n t r a t i o no f
2.5μMb o t h ,DP24a and DP24b showed superior inhibition
of human aCDase, compared to B-13. These results suggest
that neither the nitro- nor the methoxygroup inﬂuence the
potency of aCDase inhibition.
Next we wanted to evaluate alternative possibilities for
an introduction of basic amino groups for a facilitating
lysosomal enrichment. Lipid hydrolases obviously contain
large hydrophobic pocketswhich harbour the fatty acid moi-
eties of substrate lipids. Hydrophobic interaction however
often is a critical determinate in drug design. Recently we
have shown for three diﬀerent substance classes inhibiting
acid sphingomyelinase that the inhibitory potency positively
correlates with the length of hydrocarbon chains [11–13].
We hypothesize that the remarkable drop in cell lysate
aCDase inhibition from B-13 (95% inhibition) to LCL-4644 Journal of Lipids
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Figure 5: Activity of aCDase in the presence of 2.5μMo ft h e
novel analogues DP24 a–c and DP25 a,c as well as B13 and its
enantiomer ent-B13. All experiments were conducted as triplicates
and repeated at least once. P-values (two-tailed, in order of
appearance): .007, .003, .083, .006, .009, .027, .026.
(50% inhibition) is a result of the partial disruption of
the major hydrophobic interaction between the aCDase and
the positively charged fatty acid chain in LCL-464. This
problem might be circumvented by introduction of basic
moieties at sites other than the fatty acid chain. Thus
we synthesized a pyridine analogue of DP24 by reaction
of nicotinic aldehyde 1c with nitromethane. The resulting
nitrocompound 2c was reduced to the respective amine
3c and reacted with myristoyl chloride to aﬀord DP24c.
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Figure 6: IC50curve for DP24a. The IC50 value was calculated as
being 1.287μM. Each concentration was measured in triplicate.
Although DP24c provides a basic moiety, it showed at least
the same inhibition as DP24a or DP24b (Figure 5).
Interestingly, we noticed that the enantiomer of B-13
(ent-B-13 comprising S, S stereochemistry) also showed a
remarkable inhibition of a CDase, which is contradictory to
the literature data obtained with cellular lysates. A possible
explanation would be that ent-B-13 is readily cleaved by
unknown enzymes from cellular lysates.
Although early investigations did not provide evidence
for B-13 being an alternative substrate to aCDase, we wanted
to replace the biologically labile amide bond by the more
stable urea group. Thus we synthesized the urea analogues
DP25aandDP25c(Figure 4).EvaluationintheaCDaseassayJournal of Lipids 5
revealed only a slightly better inhibition, which is probably
due to the slightly increased length of the hydrophobictail of
the B-13 analogues (Figure 5).
3.Conclusion
In our preliminary in vitro studies, we were able to identify a
new B-13analogue with increased potency versusthe recom-
binant human aCDase. This new simpliﬁed compound can
easily be synthesized and oﬀers the possibility for a more
diverseseriesofB-13analogues.Moreover,wehaveproposed
a new way for introducing weakly basic isosteres in the
aromatic part of the molecule. Such a modiﬁcation does
not reduce in vitro inhibition of aCDase. In contrast, LCL
464 shows strongly reduced aCDase inhibition in vitro when
compared to B-13 meaning that the high potency in cells is
to a large extent due to lysosomal accumulation. However, it
remains to be clariﬁed whether the pyridine group of DP24c
(pKb ∼ 9) is as suitable as the tertiary amino group of LCL
464(pKb ∼ 3)forlysosomal targeting.Furthermore, ithas to
be noted that substances comprising a basic moiety for lyso-
somal enrichment may induce lysosomal permeabilization.
Comparative cellular studies will be performed in the near
future.
In the course of our initial investigation of the structure-
activity relationship of B-13 analogues, we abandoned the
introduction of a deﬁned stereochemistry at the asymmetric
carbon atom. All the inhibition studies were done with
racemic mixtures. Optical pure compounds, however, are
possible via an enantioselective Henry reaction [45, 46].
4.Experimental
4.1. Experimental Details for the Synthesis of the Inhibitors
General Procedure for the Synthesis of Henry Products 2b and
2c. To a stirred solution of aldehyde 1b or 1c (1.5mmol)
in 10mL nitromethane was added triethylamine (1mL) as
catalyst. The resulting solution was stirred at room tempera-
ture until the consumption of the aldehyde was indicated by
TLC. It was diluted with ethyl acetate (200mL), washed with
sodium hydrogen sulﬁte, sat. sodium hydrogen carbonate,
water, and brine, dried over anhydrous sodium sulfate, and
concentrated in vacuum. The crude product was puriﬁed
by column chromatography on silica gel (cyclohexane/ethyl
acetate 2:1, v/v).
General Procedure for the Reduction of Henry Products to
Aminols 3b and 3c. The Henry product (0.23mmol) was
dissolved in 5mL methanol and charged with a catalytic
amount ofpalladium on activated charcoal. The mixture was
evaporatedand aerated with hydrogen. The reaction mixture
was stirred at room temperature until the consumption of
the Henry products was indicated. The mixture was ﬁltered
throughapadofCeliteand evaporatedtodryness. Thecrude
product was puriﬁed by column chromatography on silica
gel (cyclohexane/ethyl acetate 1:1, v/v).
General Procedure for the Preparation of Amide Inhibitors
DP24 a–c. A solution of aminol (0.145mmol) in 5mL
pyridine was placed in an ice bath and treated with myristoyl
chloride (0.143mmol). The resulting solution was allowed
to come to room temperature and stirred for 16h. The
reaction was evaporated to dryness. The crude product was
dissolved and partitioned betweendichloromethane and 1M
HCl, then washed with sat. sodium hydrogen carbonate,
water, and brine, dried over anhydrous sodium sulfate, and
concentrated in vacuum. The crude product was puriﬁed
by column chromatography on silica gel (cyclohexane/ethyl
acetate 8:1, v/v).
General Procedure for the Preparation of Urea Inhibitors
DP25 a,c. To a stirred solution of aminol (0.188mmol) in
5mL acetonitrile and 5mL chloroform was added tetradecyl
isocyanate (0.376mmol). The mixture was stirred at room
temperature for 12h. The reaction mixture was evaporated
to dryness. The crude product was puriﬁed by column
chromatography on silica gel (CH2Cl2/methanol 20:1, v/v).
1-(3-Methoxyphenyl)-2-Nitroethanol2b. 300mg (2.21mmol)
aldehyde 1b gave 355mg (1.99mmol, 90%) of a pale yellow
liquid, C9H11NO4 (197g/mol). Rf (ethyl acetate) = 0.2. 1H-
NMR (CDCl3; 300MHz): δ = 2.87 (bs, 1H, OH), 3.83 (s,
3H, CH3), 4.51 (dd, J1 = 3.2Hz,J2 = 13.3Hz,1H;CH 2),
4.60 (dd, J1 = 9.4Hz,J2 = 13.3Hz,1H,CH 2), 5.43 (dd, J1 =
3.2Hz,J2 = 9.4Hz, 1H; CH), 6.90 (ddd, J1 = 1.1Hz,J2 =
2.5Hz,J3 = 8.3Hz, 1H; CHarom.), 6.97 (m, 2H; CHarom),
7.32 (dd, J1 = 8.1Hz,J2 = 8.1Hz, 1H; CHarom) ppm. 13C-
NMR (CDCl3;7 5M H z ) :δ = 55.4, 70.9, 81.2, 111.5, 114.4,
118.1, 130.1, 139.8, 160.0ppm. HR-MS p ESI calculated for
C9H11NO4 − H+ m/z = 196.0609, found: 196.0615.
2-Nitro-1-(Pyridin-3-yl)-Ethanol 2c. 200mg (1.86mmol) al-
dehyde 1c gave 250mg (1.48mmol, 79.6%) of brown oil,
C7H8N2O3 (170g/mol). Rf (ethyl acetate) = 0.05. 1H-NMR
(CDCl3; 300,1MHz): δ = 4.52 (dd, J1 = 3.6Hz, J2 =
12.8Hz,1H,CH 2), 4.61 (dd, J1 = 9.3Hz,J2 = 12.8Hz,1H,
CH2), 5.50 (dd, J1 = 3.6Hz,J2 = 9.3Hz,1H,CH),5.67(bs,
1H, OH), 7.33 (ddd, J1 = 0.6Hz,J2 = 4.9Hz,J3 = 7.9Hz,
1 H ,C H a r o m ) ,7 . 8 2( t d ,J1 = 1.7Hz,J2 = 1.7Hz,J3 = 7.9Hz,
1H, CHarom), 8.40 (dd, J1 = 1.6Hz, J2 = 4.9Hz, 1H,
CHarom), 8.48 (d, J = 2.15Hz, 1H, CHarom) ppm. 13C-
NMR (CDCl3; 75,4MHz): δ = 68.4, 81.2, 124.2, 134.7, 135.4,
147.0, 149.1ppm. HR-MS p ESI calculated for C7H7N2O3 −
H+ m/z = 169.0608, found: 169.0615.
1-(3-Methoxyphenyl)-2-Aminoethanol3b. 170mg(0.86mmol)
2b gave 124mg (0.74mmol, 86%) of a brown solid,
C9H13NO2 (167g/mol). Rf (CH2Cl2/methanol 10%) = 0.3.
1H-NMR (CDCl3; 300MHz): δ = 2.74–3.13 (m, 2H, CH2),
3.75 (s, 3H, CH3), 4.98 (d, J = 7.4Hz, 1H; CH), 6.78 (dd,
J1 = 2.1Hz, J2 = 8.1Hz, 1H; CHarom.), 6.89 (m, 2H;
CHarom), 7.21 (dd, J1 = 7.9Hz,J2 = 7.9Hz,1H;CHarom)
ppm. 13C-NMR (CDCl3;7 5 M H z ) :δ = 49.0, 60.8, 74.0,
111.4, 113.0, 118.2, 129.5, 144.2, 159.7ppm HR-MS p ESI6 Journal of Lipids
calculated for C9H13NO2 − H+ m/z = 168.1019, found:
168.1015.
2-Amino-1-(Pyridin-3-yl)-Ethanol 3c. 132mg (0.79mmol)
gave109mg(0.79mmol,quant.)ofapalebrownsolid,which
was used without puriﬁcation, C7H7N2O3 (170g/mol). Rf
(CH2Cl2/methanol 10%) = 0.05.
1-(2-Hydroxy-2-Phenylethyl)-3-Tetradecylurea DP25a.100mg
(0.73mmol)1-phenyl-2-aminoethanolgave150mg(0.40mmol,
54.5%) of a colorless solid, C23H40N2O2 (376g/mol). Rf
(CH2Cl2/methanol10%) =0.5. 1H-NMR(CDCl3;300MHz):
δ = 0.90 (t, 3 H, CH3), 1.29 (s, 22H, CH2), 3.13 (dd, J1 =
7.1Hz,J2 = 7.1Hz,2H,NCH 2), 3.31 (dd, J1 = 7.6Hz,J2 =
14.4Hz, 1H, CH), 5.67 (bs, 1H, OH), 3.55 (dd, J1 = 2.8Hz,
J2 = 14.4Hz, J3 = 7.9Hz, 1H, CHarom), 4.83 (dd, J1 =
2.7Hz,J2 = 7.5H z ,1 H ,C H a r o m ) ,5 . 5 0( 1 H ,N H u r e a ) ,5 . 8 0
(1H, NHurea), 7.28–7.30 (m, 5H, CHarom) ppm. 13CNMR
(CDCl3;7 5M H z ) :δ = 14.1, 22.7, 26.9, 29.4, 29.6, 29.7, 30.1,
31.9, 40.8, 48.7, 74.7, 125.9, 127.6, 128.4, 142.2ppm. HR-
MS p ESI calculated for C23H40N2O2 +H + m/z = 377.3163,
found: 377.3163.
1-(2-Hydroxy-2-(Pyridin-3-yl)Ethyl)-3-Tetradecylurea DP25c.
20mg (0.14mmol) crude 1-(pyridine-3-yl)-2-aminoethanol
gave 15mg (0.040mmol, 28.4%) of a colorless solid,
C22H39N3O2 (377g/mol).Rf (CH2Cl2/methanol 10%) = 0.2.
1H-NMR (CDCl3; 300MHz): δ = 0.87 (t, 3 H, CH3), 1.24
(s, 22H, CH2), 1.45 (br, 2H, CH2), 2.85 (br, 2H, NCH2), 3.12
(br, 1H, OH) 3.30–3.38 (br, 1H, CH2), 3.60 (d, J = 15.4Hz,
1H, CH2), 4.79 (br, 1H, NHurea), 4.89 (dd, J1 = 2.5Hz,
J2 = 6.9Hz, 1H, CH), 5.07 (br, 1H, NHurea), 7.31 (dd,
J1 = 3.7Hz, J2 = 8.3 H z ,1 H ,C H a r o m ) ,7 . 8 0( d ,J =
8.5Hz, 1H, CHarom), 8.48 (br, 1H, CHarom), 8.57 (br, 1H,
CHarom) ppm. 13C-NMR (CDCl3;7 5M H z ) :δ = 14.1, 22.8,
27.0,29.4,29.7, 29.8,30.2,32.0,40.3, 47.8,71.7,123.9,134.9,
138.7, 147.1, 148.0, 160.2ppm. HR-MS p ESI calculated for
C22H39N3O2 +H + m/z = 378.3115, found: 378.3118.
N-(2-Hydroxy-2-Phenylethyl)-Tetradecanamide DP24a. 100mg
(0.73mmol)1-phenyl-2-aminoethanolgave118mg(0.34mmol,
46.6%) of a colorless solid, C22H37NO2 (347g/mol). Rf
(CH2Cl2/methanol 10%) = 0.6 1H-NMR(CDCl3;300MHz):
δ = 0.90 (t, 3 H, CH3), 1.28 (s, 20H, CH2), 1.57 (br, 2H,
CH2), 2.11 (t, 2H, NCH2), 3.27 (m, 1H, CH2), 3.61 (ddd,
J1 = 3.2Hz,J2 = 6.7Hz,J3 = 13.9Hz,1H,CH 2), 4.77 (dd,
J1 = 3.1Hz,J2 = 7.9Hz, 1H, CH), 6.48 (br, 1H, NHamide),
7.31 (m, 5H, CHarom) ppm. 13C-NMR (CDCl3;7 5M H z ) :
δ = 14.1, 22.7, 25.7, 29.3, 29.4, 29.5, 29.7, 31.9, 36.6, 47.8,
73.5, 125.8, 127.7, 128.4, 141.9, 174.9ppm. HR-MS p ESI
calculated for C22H37NO2 +H + m/z = 348.2897, found:
348.2897.
N-(2-Hydroxy-2-(3-Methoxyphenyl)Ethyl)-Tetradecanamide
DP24b. 15mg (0.090mmol) 1-(3-Methoxyphenyl)-2-ami-
noethanol gave 20mg (0.053mmol, 58.9% d. Th.) of a
white solid, C23H39NO4 (377 g/mol). Rf (CH2Cl2/methanol
10%) = 0.5. 1H-NMR (CDCl3; 300MHz): δ = 0.90 (t,
3H ,C H 3), 1.27 (s, 20H, CH2), 1.62 (br, 2H, CH2), 2.20
(dd, J1 = 7.6Hz,J2 = 15.2Hz,1H,NCH 2), 2.34 (m, 1H,
NCH2), 3.82 (s, 3H, OCH3)3 . 8 7( d ,J = 8.0Hz,1H,CH),
6.00 (br, 1H, NHamide), 6.85–7.00 (m, 3H, CHarom) 7.25–
7.32 (m, 1H, CHarom) ppm. 13C-NMR (CDCl3;7 5M H z ) :
δ = 14.1, 22.7, 25.7, 29.1, 29.3, 29.4, 29.5, 29.7, 31.9, 36.6,
55.2, 73.7, 111.2, 113.3, 118.1, 129.5, 159.8ppm. HR-MS p
ESI calculated for C23H39NO3 +H + m/z = 378.3003, found:
378.3002.
N-(2-Hydroxy-2-(Pyridin-3-yl)-Ethyl)Tetradecanamide DP24c.
20.5mg (0.15mmol) crude 1-(pyridine-3-yl)-2-aminoetha-
nol gave 37mg (0.106mmol, 71.6%) of a colorless solid,
C21H36N2O2 (348g/mol). Rf (CH2Cl2/methanol 10%) = 0.4.
1H-NMR (CDCl3; 300MHz): δ = 0.87 (t, 3 H, CH3), 1.27
(s, 20H, CH2), 1.58 (m, 2H, CH2), 2.20 (m, 2H, COCH2),
3.12 (br, 1H, OH) 3.40 (dd, J1 = 7.1Hz,J2 = 14.1Hz,1H,
CH2), 3.69 (ddd, J1 = 3.1Hz, J2 = 6.4Hz,J3 = 14.2Hz,
1H, CH2), 4.91 (dd, J1 = 2.6Hz,J2 = 7.0Hz,1H,CH),5.26
(br, 1H, NHamide), 7.31 (dd, J1 = 5.0Hz,J2 = 7.4Hz,1H,
CHarom), 7.78 (d, J = 7.9H z ,1 H ,C H a r o m ) ,8 . 4 8( b r ,1 H ,
CHarom), 8.54 (br, 1H, CHarom) ppm. 13C-NMR (CDCl3;
75MHz):δ =14.1,22.7,25.7,29.3,29.4,29.5,29.7,31.9,36.5,
47.6, 71.8, 123.7, 134.4, 147.2, 148.4, 175.4ppm. HR-MS p
ESI calculatedfor C21H36N2O2 +H + m/z = 349.2850, found:
349.2852.
4.2. Micellar aCDase Assay. The micellar aCDase assay has
been described previously [47].
Brieﬂy, assays were performed in the presence of sodium
acetate buﬀer (250mM, pH 4.0), 5mM EDTA, 0.7% (w/v)
Triton X-100, 0.4% (w/v) Tween 20, 0.4% (w/v) Igepal CA-
630, and 17nmol/50μL N-Lauroyl-D-Erythro-Sphingosine.
The activity was determined with 60μLo fb u ﬀer, 35μL
undiluted enzyme solution (43,7μg/mL), and 5μLo f5 0μM
inhibitor solution in DMSO which gave 100μL total volume
with 2.5μM inhibitor concentration. Tests were incubated
for 30min at 37◦C, the reactions terminated with 800μl
chloroform/methanol 2:1 (v/v) and 200μL saturated aque-
ous ammonium carbonate solution, and C14-a n dC 16-
sphinganin in methanol (500pM of each) were added.
Afterwards the mixtures were centrifuged at 10000×gf o r
5min, the chloroform phase was dried and redissolved
in 50μL ethanol and incubated 10min at 50◦C. 50μLo -
phthalaldehyde solution was added. The mixture was incu-
bated for 5min at room temperature. Samples were diluted
with 0.9mL HPLC buﬀer (acetonitrile/2mM KH2PO4,p H
7.0, 9/1 (v/v)) and 0.1mL 5mM KH2PO4 buﬀer (pH 7.0,
90:10, v/v). Aliquots were injected immediately onto an
RP-C18 Polaris A 5μm (PN A 2000-250×100)—column
by Varian. Lipids were eluted with mixtures out of water
containing 1% acetonitrile and acetonitrile containing 1%
water with a ﬂow of 1mL/min. Excitation wavelength
is λ = 355nm, emission wavelength is λ = 435nm.
For IC50 determination, the inhibitor concentrations were
varied as indicated. All experiments were done in tripli-
cate.Journal of Lipids 7
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